首页   >  
Angiogenesis/Protein Tyrosine Kinase
  >  
BTK

所有产品分类

所有产品

信号通路

研究领域

天然产物

抗体

多肽

催化剂

杂质对照品

医药中间体

基础原料

BTK

结构式 货号 产品名称 CAS号
RN983 结构式
BCP44110 RN983 1423129-83-2
RN983 is a selective BTK enzyme inhibitor.
BIIB068 结构式
BCP44097 BIIB068 1798787-27-5
BIIB068 is a potent, selective, reversible and orally active BTK inhibitor.
TL-895 结构式
BCP44090 TL-895 1415823-49-2
TL-895 is a potent, orally active, ATP-competitive, and highly selective irreversible BTK inhibitor with an IC50 and a Ki of 1.5 nM and 11.9 nM, respectively.
Tolebrutinib 结构式
BCP33289 Tolebrutinib 1971920-73-6
Tolebrutinib, also known as SAR442168, is a Bruton tyrosine kinase inhibitor.
Rilzabrutinib 结构式
BCP43077 Rilzabrutinib 1575596-29-0
Rilzabrutinib, also known as PRN1008, is a reversible covalent, selective and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK).
Pirtobrutinib 结构式
BCP42730 Pirtobrutinib 2101700-15-4
Pirtobrutinib is a Bruton's tyrosine kinase (BTK) inhibitor and antineoplastic agent.
CNX-500 结构式
BCP40963 CNX-500 1202758-21-1
CNX-500 is a probe consisting of a covalent Btk inhibitor chemically linked to biotin.
Olmutinib dihydrochloride 结构式
BCP38296 奥莫替尼双盐酸盐 1842366-97-5
Olmutinib is an orally available, mutant-selective third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that is being developed for treatment of advanced and metastatic EGFR mutation-positive non-small cell lung cancer (NSCLC).
Orelabrutinib 结构式
BCP37603 奥布替尼 1655504-04-3
Orelabrutinib is a potent, orally active, and irreversible Bruton's tyrosine kinase (BTK) inhibitor, being developed by InnoCare Pharma, for the treatment of chronic lymphocytic leukaemia.
Remibrutinib 结构式
BCP36887 Remibrutinib 1787294-07-8
Remibrutinib, also known as LOU064, is a Bruton's tyrosine kinase inhibitor.
123下一页末页共 41 条记录 1 / 5 页 
2853530910